title: No association between pre-diagnostic plasma C-reactive protein concentration and subsequent prostate cancer.
abstract: BACKGROUND
  We evaluated the association of pre-diagnostic plasma concentration of C-reactive protein, a sensitive, but non-specific indicator of inflammation, with subsequent risk of prostate cancer.
  
  
  METHODS
  Included were 264 histologically confirmed prostate cancer cases and 264 age-matched controls who were participants in the CLUE II cohort of Washington County, MD. C-reactive protein was measured using a high-sensitivity immunoturbidimetric assay. Odds ratios (ORs) and 95% confidence intervals (CI) were estimated from conditional logistic regression models by fourth of the C-reactive protein distribution with cutpoints based on the controls. The median concentrations from the lowest to highest fourth were 0.41, 1.03, 1.90, and 4.53 mg/L.
  
  
  RESULTS
  Geometric mean plasma concentrations did not differ between the cases (1.24 +/- 2.94 mg/L) and controls (1.41 +/- 2.97 mg/L; P = 0.16). Compared to the bottom fourth, the ORs (95% CI) of prostate cancer were 1.29 (0.80-2.08), 0.98 (0.61-1.58), and 0.95 (0.57-1.58) for the second, third, and highest fourths (P trend = 0.66). These findings were unchanged after adjusting for body mass index (BMI) and cigarette smoking status or after excluding men with markedly elevated C-reactive protein, cases diagnosed during the first 2 years of follow-up, or controls who never had a PSA test. These findings did not differ by stage or grade of prostate cancer.
  
  
  CONCLUSIONS
  Pre-diagnostic plasma concentration of C-reactive protein was not associated with subsequent risk of prostate cancer.
authors.affiliation: Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA. eplatz@jhsph.edu
authors.forename: Elizabeth A
authors.initials: EA
authors.lastname: Platz
authors.forename: Angelo M
authors.initials: AM
authors.lastname: De Marzo
authors.forename: Thomas P
authors.initials: TP
authors.lastname: Erlinger
authors.forename: Nader
authors.initials: N
authors.lastname: Rifai
authors.forename: Kala
authors.initials: K
authors.lastname: Visvanathan
authors.forename: Sandra C
authors.initials: SC
authors.lastname: Hoffman
authors.forename: Kathy J
authors.initials: KJ
authors.lastname: Helzlsouer
mesh_terms: D000368:Aged; D002097:C-Reactive Protein / Q000032:analysis*; D016022:Case-Control Studies; D006801:Humans; D007118:Immunoassay; D007249:Inflammation; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000209:etiology*; D012307:Risk Factors; D012680:Sensitivity and Specificity
chemical_list: D002097:C-Reactive Protein